Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Cancels Telavancin Advisory Panel Review 3 Days Before Meeting

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA cancelled a Feb. 27 advisory panel meeting for Astellas Pharma/Theravance's telavancin to allow the agency time "to review and resolve several outstanding issues" in the NDA, the agency said Feb. 25

You may also be interested in...



Astellas’ Telavancin Application Withdrawn In Europe, To Be Reworked With HAP Indication

Astellas has withdrawn its application to market Vibative (telavancin) for adult complicated skin and soft tissue infections in Europe, but plans to submit a new application in 2009 that includes an indication for hospital-acquired pneumonia

Astellas’ Telavancin Application Withdrawn In Europe, To Be Reworked With HAP Indication

Astellas has withdrawn its application to market Vibative (telavancin) for adult complicated skin and soft tissue infections in Europe, but plans to submit a new application in 2009 that includes an indication for hospital-acquired pneumonia

Astellas, Daiichi Move Ahead With Factor Xa Programs

Astellas and Daiichi Sankyo both are on track to proceed to Phase III for their respective oral Factor Xa inhibitors, the companies indicated in second quarter earnings presentations on Nov. 7

Related Content

UsernamePublicRestriction

Register

LL021506

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel